Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio-Immunology

Collaboration aims to discover novel bispecific proteins targeting immune modulators and inflammatory pathways implicated in cardiovascular disease Palo Alto, California, and Zhuhai, China – February 26, 2024 – Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, today announced a multi-year research collaboration agreement. […]

Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio-Immunology Read More »

Bitterroot Bio to Present Preclinical Research at American Heart Association Conference

PALO ALTO, Calif. – Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, has been selected to present research at the upcoming American Heart Association Scientific Sessions conference, which will take place from November 11-13, 2023 at the Pennsylvania Convention Center in Philadelphia, PA. The abstract, titled “Blockade of CD47 Using

Bitterroot Bio to Present Preclinical Research at American Heart Association Conference Read More »

Bitterroot Bio Launches Out of Stealth with $145 million Series A Financing to Develop Transformative Medicines in Cardio-immunology

Founders, Executive Team, and Advisors are recognized scientific and clinical pioneers in the fields of immunology and cardiology Series A financing co-led by ARCH Venture Partners and Deerfield Management with participation from GV, Koch Disruptive Technologies, Alexandria Venture Investments, and others PALO ALTO, Calif. – Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies

Bitterroot Bio Launches Out of Stealth with $145 million Series A Financing to Develop Transformative Medicines in Cardio-immunology Read More »

Bitterroot Bio is a privately held company dedicated to the pursuit of breakthroughs in cardiovascular medicine. We are committed to improving the lives of patients, and we believe that focusing on research and development is the best way to achieve that goal. We do not engage in, support, or advocate on behalf of political, social, environmental, or other causes that are unrelated to our mission.
Scroll to Top